DEEP LEVEL INVESTIGATION OF INGAAS ON INP LAYER
2017 CHINA SEMICONDUCTOR TECHNOLOGY INTERNATIONAL CONFERENCE (CSTIC 2017)
Authors: Wang, Chong; Simoen, Eddy; AliReza, Alian; Sioncke, Sonja; Collaert, Nadine; Claeys, Cor; Li, Wei
Abstract
Deep level traps in lattice-matched In0.47Ga0.53As epitaxial layers grown by MBE on InP substrates have been studied by Deep Level Transient Spectroscopy (DLTS) on Al2O3/InGaAs Metal-Oxide-Semiconductor (MOS) capacitors. The impact of different surface passivation steps and a post-gate-deposition Forming Gas Annealing (FGA) has been studied. It is shown that spectra are dominated by a near mid gap electron trap in the depletion region, with activation energy in the range 0.37 eV to 0.42 eV. At the same time, a broad background distribution of interface states is found as well, which is significantly reduced by the FGA. Detailed carrier trapping studies have been carried out to identify the origin of the grown-in electron traps, which are shown to be of point defect behavior.
Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch
Expert Opinion On Drug Safety
Authors: Rafaniello, Concetta; Pozzi, Marco; Pisano, Simone; Ferrajolo, Carmen; Bertella, Silvana; Sportiello, Liberata; Carnovale, Carla; Sullo, Maria Giuseppa; Cattaneo, Dario; Gentili, Marta; Rizzo, Renata; Pascotto, Antonio; Mani, Elisa; Villa, Laura; Riccio, Maria Pia; Sperandeo, Serena; Bernardini, Renato; Bravaccio, Carmela; Clementi, Emilio; Molteni, Massimo; Rossi, Francesco; Radice, Sonia; Capuano, Annalisa
Abstract
Objective: Gap in knowledge on benefit/risk ratio of second generation antipsychotics (SGA) in the paediatric population represents a challenge for the scientific community. This study aims to analyse all suspected adverse drug reactions (ADRs) to SGA observed during the study period; compare the safety profiles of risperidone and aripiprazole; evaluate the effect of switching from risperidone to aripiprazole or to a first generation antipsychotic (FGA). Methods: Prospective analysis of spontaneously reported ADRs concerning 184 paediatric outpatients between 2012 and 2014.; clinical outcomes of drug switch were evaluated. Results: Out of the 184 patients, 130 experienced at least one ADR; ADRs were usually not serious and more frequently associated with aripiprazole. Switching to aripiprazole was associated with better results than switching to FGAs in the Clinical Global Impression scale-Efficacy (CGI-E) scores (p = 0.018), Disturbed behaviour checklist-parents (DBC-P) self-absorption subscale (p = 0.010); only a trend for difference between changing to aripiprazole vs FGAs in the DBC-P total score (p = 0.054) and social relating subscale (p = 0.053) was observed. Conclusions: SGAs safety data were consistent with the ones already known; however, there is still a need to improve the knowledge in pharmacovigilance field among clinicians. Switching to aripiprazole may be a valid alternative to risperidone.
COA
Publication 
Loading ......
